By Chris Wack
Trevi Therapeutics shares were up 72% at $4.27 after the company said it saw had a positive outcome from the planned sample size re-estimation for its ongoing Phase 2b trial in idiopathic pulmonary fibrosis patients with chronic cough.
Shares in the New Haven, Conn., company hit their 52-week high of $4.50 earlier in the session, and are up 222% in the past 12 months.
The clinical-stage biopharmaceutical company said it doesn't require any changes to the current sample size for the trial.
The trial has reached 75% of the targeted enrollment, and topline results from the full trial continue to be expected in the first half of 2025.
The analysis was conducted on the highest dose in the trial after 50% of the initial targeted trial enrollment, or 80 patients, completed the six weeks of treatment. Based on the analysis, it was recommended that the trial should continue as planned to maintain the pre-specified conditional power of 80% or greater.
The primary efficacy endpoint for the trial is the relative change in 24-hour cough frequency at the end of week six versus baseline. The trial will also explore secondary endpoints, including patient reported outcome measures for cough.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 12, 2024 10:17 ET (15:17 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。